Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.
Kezar Life Sciences (KZR) is a clinical-stage biotechnology company pioneering novel small molecule therapeutics for autoimmune disorders and oncology. This page provides authoritative updates on corporate developments, clinical research, and strategic initiatives essential for informed decision-making.
Access real-time updates on KZR-616 clinical trials, regulatory milestones, and scientific advancements alongside financial disclosures and partnership announcements. Our curated news collection serves investors, researchers, and healthcare professionals seeking comprehensive insights into the company’s progress.
Key coverage areas include immunoproteasome inhibitor developments, trial phase updates, intellectual property news, and collaborative research efforts. All content undergoes rigorous verification to ensure alignment with SEC filings and peer-reviewed publications.
Bookmark this page for streamlined access to KZR’s latest material events. Combine our news monitoring with SEC filings and medical journals for complete due diligence.
Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotech firm, announced a nonqualified stock option grant to purchase 80,000 shares at $0.71 per share.
The stock option, granted to a new employee on June 3, 2024, is in line with Nasdaq Listing Rule 5635(c)(4). The grant is part of Kezar's strategy to attract top talent.
The options will vest over four years: 25% after the first year, with the remainder vesting monthly. This grant is material to the individual’s employment agreement and is part of Kezar's 2022 Inducement Plan.
Kezar Life Sciences, a clinical-stage biotechnology company listed on Nasdaq (KZR), announced that its CEO, Chris Kirk, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 12:30 pm ET in New York. The company focuses on developing novel small molecule therapeutics for immune-mediated diseases and cancer. The event will be webcasted live and available on Kezar's website for 90 days post-event.
Kezar Life Sciences, Inc. reported its first quarter 2024 financial results and business update, including progress in clinical trials for zetomipzomib in lupus nephritis and autoimmune hepatitis, and dose expansion for KZR-261 in melanoma. Cash, cash equivalents, and marketable securities totaled $179.8 million. R&D expenses decreased to $17.2 million, while G&A expenses increased to $6.5 million. Net loss was $21.7 million for the quarter.
Kezar Life Sciences, Inc. granted two employees nonqualified stock options to purchase 164,000 shares of common stock at $0.84 per share under NASDAQ Listing Rule 5635(c)(4). The options will vest over four years, with 25% on the first anniversary and 1/48th monthly thereafter, contingent on continued employment.
FAQ
What is the current stock price of Kezar Life Sciences (KZR)?
What is the market cap of Kezar Life Sciences (KZR)?
